PHARMA MAR, S.A. «...1112131415...» Page 14 out of 23 22/09/2021 08:27 PHARMA MAR, S.A. On business and financial situation The Company announces the approval of Zepzelca® (lurbinectedin) for the treatment of metastatic Small Cell Lung Cancer in Singapore. Register number: 11772 14/09/2021 08:28 PHARMA MAR, S.A. On business and financial situation The Company announces the approval of Zepzelca® (lurbinectedin) for the treatment of metastatic Small Cell Lung Cancer in Australia Register number: 11654 01/09/2021 08:26 PHARMA MAR, S.A. On business and financial situation The Company announces the approval of Zepzelca® (lurbinectedin) for the treatment of metastatic Small Cell Lung Cancer in the United Arab Emirates Register number: 11447 31/08/2021 16:53 PHARMA MAR, S.A. Board of Directors Regulations La sociedad remite el reglamento del Consejo de Administración Register number: 11435 29/07/2021 16:35 PHARMA MAR, S.A. On corporate governance The Company informs of changes in the composition of the Appointments and Compensation and Sustainability Committee, and in the Audit Committee, as well as the amendments of the Board of Directors Regulations. Register number: 11028 29/07/2021 16:24 PHARMA MAR, S.A. Other relevant information - On business and financial situation The Company sends press release regarding first half 2021 results and announces a conference call with analysts and investors. Register number: 11026 29/07/2021 16:16 PHARMA MAR, S.A. Half-yearly financial reports and audit reports/limited audit review La sociedad remite información financiera del primer semestre de 2021 Register number: 11022 28/07/2021 11:20 PHARMA MAR, S.A. On business and financial situation COMP, from the EMA, has given its positive opinion for the approval of Orphan Drug status to Zepzelca® (lurbinectedin) for the treatment of Mesothelioma Register number: 10916 13/07/2021 11:21 PHARMA MAR, S.A. Liquidity and counterparty agreements The Company enters into a liquidity agreement with JB Capital Markets, Sociedad de Valores, S.A.U. Register number: 10583 25/06/2021 14:30 PHARMA MAR, S.A. Liquidity and counterparty agreements The Company announces the termination of the liquidity agreement entered into on June, 4, 2018 with JB Capital Markets, Sociedad de Valores, S.A.U. Register number: 10195 Page 14 out of 23 «...1112131415...»
